Filing Details

Accession Number:
0001209191-20-009847
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-02-14 20:57:04
Reporting Period:
2020-01-15
Accepted Time:
2020-02-14 20:57:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1501756 Adverum Biotechnologies Inc. ADVM Biological Products, (No Disgnostic Substances) (2836) 205258327
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1614875 Mehdi Gasmi C/O Adverum Biotechnologies, Inc.
1035 O'Brien Drive
Menlo Park CA 94025
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-15 88,496 $0.00 321,418 No 4 A Direct
Common Stock Disposition 2020-02-12 31,451 $11.33 289,967 No 4 F Direct
Common Stock Disposition 2020-02-12 15,494 $15.05 258,979 No 4 F Direct
Common Stock Acquisiton 2020-02-12 10,000 $4.80 268,979 No 4 M Direct
Common Stock Disposition 2020-02-12 10,000 $15.07 258,979 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 F Direct
No 4 F Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-02-12 10,000 $0.00 10,000 $4.80
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
178,000 2026-02-11 No 4 M Direct
Footnotes
  1. Represents shares of Common Stock issued upon vesting of restricted stock units with performance-based vesting pursuant to the Separation Agreement between the Reporting Person and Issuer, dated July 30, 2019.
  2. Reflects shares withheld by the Issuer upon vesting of restricted stock units to satisfy withholding tax obligations.
  3. Shares sold pursuant to a 10b5-1 plan.
  4. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $15.00 to $15.13. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  5. Twenty-five percent (25%) of the total number of shares subject to the option vest and become exercisable on the first anniversary of the Vesting Commencement Date, and 1/48th of the total number of shares subject to the option vest and become exercisable each month thereafter, such that all of the shares subject to the option shall become vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service with the Issuer on each such vesting date.